Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy (NCT05487417) | Clinical Trial Compass
CompletedPhase 4
Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
China189 participantsStarted 2022-11-01
Plain-language summary
Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) of patients with ischemic stroke, indicating that minocycline is a potential neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no clinical research in this area at present. Therefore, investigators carry out the study on the effect of minocycline in patients with acute anterior circulation ischemic stroke after mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion;
. Age 18-85 years old;
. The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging;
. The time of onset 6-24 hours, DWI shows an infarct volume less than 1/3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6;
. Preoperative NIHSS score ranges from 6 to 30 points;
. Sign the informed consent form;
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial has already completed, would my doctor be able to access the results to see whether minocycline actually reduced infarct volume by day 5, and what that might mean for my treatment options?
2Minocycline is an antibiotic being studied here as a brain-protective drug alongside clot-removal therapy — is that a combination my doctor thinks could be relevant to my situation, given the type of ischemic stroke I had?
3This was a Phase 4 trial, which means minocycline is already an approved drug being studied in a new use — does that change what my doctor already knows about its safety profile, and are there any risks specific to taking it right after a stroke?
4The trial measured changes in infarct volume — the size of the damaged area in the brain — between the time of stroke and day 5, so could my doctor explain whether that kind of outcome would translate into a real difference in recovery or disability for someone in my position?
5Since the trial is completed and I can't enroll, is there any other ongoing research or off-label use of minocycline after stroke that my doctor thinks is worth discussing as part of my care plan?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. There are contraindications for mechanical thrombectomy;
. No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b;
. There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc;
. There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction;
. Renal insufficiency or hepatic insufficiency (serum creatinine \>2.0 mg/dL or 180 µmol/L; liver function greater than 3 times the normal value);
. Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months;
. There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results;
. Pre-existing neurological deficits or history of dementia;